Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study

Osteoarthritis and Cartilage

Volumn 21, Issue 1, 2013, Pages 22-27

  Zegels, B ^a   Crozes, P ^b   Uebelhart, D ^c   Bruyere O ^d   Reginster, J Y ^a,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Rhumatologie   (France)

^c Valmont   (Switzerland)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chondroitin; Equivalence; Knee osteoarthritis; Symptoms

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 4 SULFATE PLUS CHONDROITIN 6 SULFATE; CHONDROITIN 6 SULFATE; CHONDROSULF; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; CYSTITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRAL CANAL STENOSIS; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; AGED; CHONDROITIN SULFATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84871919556     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.09.017     Document Type: Article

References (27)

1. Arden N., Nevitt M.C. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3-25.
2. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
3. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through. Osteoarthritis Cartilage January 2009, 18:476-499.
4. Bruyere O., Burlet N., Delmas P.D., Rizzoli R., Cooper C., Reginster J.Y. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008, 9:165.
5. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
6. Reginster J.Y., Heraud F., Zegels B., Bruyere O. Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Rev Med Chem 2007, 7:1051-1061.
7. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
8. Michel B.A., Stucki G., Frey D., De Vathaire F., Vignon E., Bruehlmann P., et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005, 52:779-786.
9. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S19-S21.
10. Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010, 18(Suppl 1):S28-S31.
11. Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate *. Curr Med Res Opin 2008, 24:3029-3035.
12. Bruyere O., Reginster J.Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007, 24:573-580.
13. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049.
14. Lequesne M. Indices of severity and disease activity for osteoarthritis. Semin Arthritis Rheum 1991, 20:48-54.
15. Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987, 65:85-89.
16. Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cartilage 1998, 6(Suppl A):25-30.
17. Uebelhart D., Malaise M., Marcolongo R., de Vathaire F., Piperno M., Mailleux E., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
18. Bucsi L., Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998, 6(Suppl A):31-36.
19. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996, 23:1385-1391.
20. Blotman F., Loyau G. Clinical trial with chondroitin sulfate in gonarthrosis. Osteoarthritis Cartilage 1993, 1:68.
21. Richter A., Anton S.E., Koch P., Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 2003, 25:2307-2335. discussion 06.
22. Eraker S.A., Kirscht J.P., Becker M.H. Understanding and improving patient compliance. Ann Intern Med 1984, 100:258-268.
23. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
24. Andrejak M., Genes N., Vaur L., Poncelet P., Clerson P., Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000, 13:184-190.
25. Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., Przybeck T.R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990, 150:1881-1884.
26. Bruyere O., Scholtissen S., Neuprez A., Hiligsmann M., Toukouki A., Reginster J.Y. Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ 2009, 12:356-360.
27. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.